ASH 2020 | Novel myelofibrosis-associated anemia treatments in Phase II trials
Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines two current trials (NCT01712308, NCT03194542) of novel therapies targeting anemia in myelofibrosis (MF). 60% of MF patients develop anemia within a year of diagnosis, and transfusion dependency predicts worse survival and quality of life, as well as compromising the delivery of JAK inhibitors. There are currently no approved therapies for MF-associated anemia. Two recent Phase II trials are addressing this unmet need: (1) ACE-536-MF-001 is trialling luspatercept, an erythroid maturation agent shown to increase hemoglobin in myelodysplastic syndrome patients; (2) a study of sotatercept, an activin receptor type IIA ligand trap. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Srdan Verstovsek, MD, PhD, has received research support for clinical studies from Incyte, Roche, NS, Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Ital Pharma, Protagonist and Kartos.
